Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
With
Janssen, LP
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years on the day of the first prescription of the study drug (= index date) during study selection window
Diagnosis of NVAF on start date of study or anytime during 365 days before this date
Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date)
Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.
You may not be if
Patients with valvular AF
Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date
Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period
Prescriptions of \< 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort